Tofogliflozin anhydrous
As of the edition of 20 October 2026, Tofogliflozin anhydrous is a small molecule: marketed, first approved in 2014 (JP); acts on SLC5A2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2014
- Kind
- Small molecule
- Brand name
- Apleway
- First approved
- 24 March 2014 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Sanofi; 2 holders in all
- Registered trials
- 10, 0 stopped early
- Disease areas
- Hormones; Nutrition and metabolism; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Tofogliflozin anhydrous.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC5A2 | Sodium/glucose cotransporter 2 | P31639 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 3 | 2 | 1 | 0 |
| Phase 4 | 2 | 2 | 0 | 0 |
| All trials | 10 |